75 related articles for article (PubMed ID: 26686802)
1. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
2. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
3. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer.
Hao Y; Wolfram V; Cook J
Clinicoecon Outcomes Res; 2016; 8():293-303. PubMed ID: 27382319
[TBL] [Abstract][Full Text] [Related]
4. EORTC QLQ-C30 general population normative data for the United States.
Rogge AA; Liegl G; Snyder C; Rose M; Nolte S;
Eur J Cancer; 2024 May; 202():114030. PubMed ID: 38552543
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
[TBL] [Abstract][Full Text] [Related]
6. Health-Related Quality of Life Assessment in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy: Real-World Experience in the READT Study.
Lim J; Ng CF; Wei Y; Ong TA; Chu PS; Chan WKW; Huang CY; Feng KK; Teoh JY; Xu N; Low JW; Yeoh WS; Chiu PK; Yee CH; Leung SCH
World J Mens Health; 2024 Apr; 42(2):449-459. PubMed ID: 37853536
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life after a diagnosis of bladder cancer: a longitudinal survey over the first year.
Rogers Z; Glaser A; Catto JWF; Bottomley S; Jubber I; Kotwal S; Brittain P; Gill J; Rogers MA; Dooldeniya MD; Koenig P; Cresswell J; Chahal R; Bryan N; Smith NJ; Pritchard K; Abbasi Z; Mason SJ; Absolom K; Downing A
BJU Int; 2024 Apr; 133(4):460-473. PubMed ID: 38031657
[TBL] [Abstract][Full Text] [Related]
8. Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
Kregting LM; Vrancken Peeters NJMC; Clarijs ME; Koppert LB; Korfage IJ; van Ravesteyn NT
Int J Cancer; 2024 Jul; 155(1):117-127. PubMed ID: 38478916
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Content Validity of Preference-Based Measures in Cancer.
Gibson AEJ; Longworth L; Bennett B; Pickard AS; Shaw JW
Value Health; 2024 Jan; 27(1):70-78. PubMed ID: 37879402
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.
Dixit J; Gupta N; Kataki A; Roy P; Mehra N; Kumar L; Singh A; Malhotra P; Gupta D; Goyal A; Rajsekar K; Krishnamurthy MN; Gupta S; Prinja S
Health Qual Life Outcomes; 2024 Mar; 22(1):26. PubMed ID: 38481231
[TBL] [Abstract][Full Text] [Related]
11. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
Flanders SC; Kim J; Wilson S; Braziunas J; Greenfield S; Billimek J; Lechpammer S; Lin DW; Karsh L; Quinn DI; Shevrin D; Shore ND; Symanowski JT; Penson DF
Future Oncol; 2018 Mar; 14(6):527-536. PubMed ID: 29417827
[TBL] [Abstract][Full Text] [Related]
12. Correction: Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2024 May; 33(5):1433-1435. PubMed ID: 38457055
[No Abstract] [Full Text] [Related]
13. Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.
Finch AP; Gamper E; Norman R; Viney R; Holzner B; King M; Kemmler G;
Pharmacoeconomics; 2021 Sep; 39(9):1085-1098. PubMed ID: 34216380
[TBL] [Abstract][Full Text] [Related]
14. Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France.
Smith AB; Hanbury A; Beitia Ortiz de Zarate I; Hammes F; de Pouvourville G; Buesch K
Patient Relat Outcome Meas; 2021; 12():237-246. PubMed ID: 34285619
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer.
Pollard ME; Moskowitz AJ; Diefenbach MA; Hall SJ
Asian J Urol; 2017 Jan; 4(1):37-43. PubMed ID: 29264205
[TBL] [Abstract][Full Text] [Related]
16. Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
Caffo O; Lunardi A; Trentin C; Maines F; Veccia A; Galligioni E
Curr Drug Targets; 2016; 17(11):1301-8. PubMed ID: 26721408
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Sung WWY; Choi HCW; Luk PHY; So TH
Front Oncol; 2021; 11():627083. PubMed ID: 33718198
[TBL] [Abstract][Full Text] [Related]
18. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; Coenen JLLM; van Moorselaar RJA; van den Berg P; Geenen MM; Mehra N; Hendriks MP; Lampe MI; van de Luijtgaarden ACM; Peters FPJ; Roeleveld TA; Smilde TJ; de Wit R; van Oort IM; Gerritsen WR; Uyl-de Groot CA
Clin Genitourin Cancer; 2020 Jun; 18(3):e233-e253. PubMed ID: 31883940
[TBL] [Abstract][Full Text] [Related]
19. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
[TBL] [Abstract][Full Text] [Related]
20. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.
Murasawa H; Sugiyama T; Matsuoka Y; Okabe T; Hino A; Tanaka N; Sugimoto M; Oyama M; Fujimoto K; Horie S; Noto S; Shimozuma K
Qual Life Res; 2019 Sep; 28(9):2383-2391. PubMed ID: 31025290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
